Introduction
Cystic fibrosis (CF) is a multiorgan disease due to mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator) which results in epithelial electrolyte transport abnormalities leading to defective clearance of secretions [1 ] . Pulmonary disease remains the main cause of morbidity and mortality in CF [2, 3] . However, other complications such as cystic fibrosis liver disease (CFLD) are now of increasing importance both from a clinical and research perspective [1 , [2] [3] [4] 5 ] .
Epidemiology
The prevalence of CFLD varies depending on the criteria used to define liver disease [1 , 3, 4] . Almost all children will at some time have evidence of liver abnormalities, including abnormal liver biochemistry, changes on ultrasound or hepatomegaly [1 , 3, 4] . At postmortem, changes ranging from focal biliary cirrhosis to multilobular cirrhosis have been reported as incidental findings in up to 70% of specimens. However, less than 10% of children with CF have clinically significant liver disease with portal hypertension [3, 6] , and there is now general agreement that CFLD should only be diagnosed when there is clinically manifest liver disease with evidence of multilobular cirrhosis and portal hypertension [3] .
Suggestions that the prevalence of liver disease in CF is increasing and that the progression of liver fibrosis to cirrhosis is contributing to increasing adverse outcomes in the CF population need to be viewed with caution [1 ,5 ] . It is likely that the apparent increases in nonpulmonary CF complications such as CFLD may be in part explained by increasing awareness, a change in diagnostic criteria together with increasing accuracy of diagnosis, in addition to the improved outcome for pulmonary complications of CF.
Pathophysiology
Cystic fibrosis liver disease is an unusual form of liver disease characterized by nonuniform portal tract abnormalities termed focal biliary cirrhosis [3] . The localization of the damage to the intrahepatic bile ducts leading to portal tract fibrosis with preserved hepatic architecture is characteristic of CFLD. The clinical significance of this abnormality, in contrast to other types of cirrhosis, is that portal hypertension and its sequelae such as gastrointestinal haemorrhage can be prominent features of the
Purpose of review
This review looks at what is currently known about liver disease in cystic fibrosis (CF) in light of the literature over the past year, and what the ongoing challenges are from a clinical and research perspective for the optimal management of cystic fibrosis liver disease (CFLD).
Recent findings
Patients with CF who develop clinically significant liver disease have a worse overall phenotype, and whereas there is no definite evidence that they have a shorter life expectancy, longer follow-up is required to determine if liver disease is a risk factor for mortality in CF. The development of the ferret and pig animal models of CF with multiorgan involvement is an important breakthrough which will enhance our understanding of the pathogenesis of CFLD, and with which it is hoped novel therapeutic targets for the treatment of CFLD will be identified. Summary Whereas there is still no effective treatment for liver disease in CF, recent developments of animal models of CFLD will enhance our capacity to develop new therapeutic targets and reduce the impact of liver disease on mortality in CF. disorder without significant hepatocellular failure [3] . Therefore with careful management of varices, many children maintain good synthetic function and deaths due to variceal haemorrhage are uncommon [7] .
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Diagnosis of cystic fibrosis liver disease
The subtle nature of CFLD makes early detection difficult, and there are no clinical or laboratory tests which are confirmatory until portal hypertension is well established [3] . It is clear from the literature that a significant number of children will have a range of abnormalities on routine ultrasound, ranging from 'benign' fatty infiltration to evidence of portal hypertension with varices [1 ,3]. The challenge for clinicians is to distinguish, at an early stage, CF patients with liver abnormalities who will progress to more severe disease with portal hypertension.
There is no gold standard for the diagnosis of CFLD, and the experienced hand of a paediatric hepatologist still remains the optimal method of diagnosis [8] . Whereas liver biopsy still is an important diagnostic tool in other liver diseases, the patchy nature of CFLD, coupled with the risks of general anaesthetic in CF, and the lack of an effective treatment if a diagnosis of CFLD is confirmed, limit the use of liver biopsy in CFLD [3] . Using a dual pass liver biopsy with ultrasound guidance, Lewindon et al. [9 ] reported that hepatic fibrosis predicts the development of clinically significant liver disease with portal hypertension at follow-up. However, of the eight children who developed portal hypertension during follow-up only four had a fibrosis score of 3 or more (Scheuer F0-F4 staging system) at baseline, whereas seven of the eight had abnormal ultrasound findings at baseline. Further research is required before liver biopsy can be recommended for routine use in the diagnosis of CFLD.
Whereas it is well recognized that ultrasound cannot distinguish liver fibrosis from fatty changes, nodularity of the liver parenchyma or an irregular liver edge on ultrasound is highly predictive of the development of portal hypertension in CFLD, even in the absence of significant change in liver size [10] . Transient elastography (Fibroscan Echosens, Paris, France) is a noninvasive and reproducible technique used to measure liver stiffness in a variety of fibrotic liver conditions. The stiffer the liver tissue is, the faster the wave generated by the transducer is propagated resulting in higher median elasticity values in patients with liver fibrosis. Transient elastography has been evaluated for the detection of liver disease in children with CF [11,12 ,13 ] . It may also be useful to evaluate the presence of oesophageal varices, as median elasticity values are higher in CFLD patients with varices compared to those with no varices. This could reduce the need for gastroduodenoscopy [12 ] , and it would be particularly useful if liver elastography values could distinguish varices which require banding from smaller varices. However, further studies are required to define the optimal threshold values for elastography to distinguish those with clinically significant varices from those with small or no varices.
Genetic variability and disease severity
The onset of liver disease is in childhood, with diagnosis usually confirmed in the second decade [1 ,3]. The reason for liver disease progression in only a minority of patients with CF is unknown. CFLD has not been reported to develop de novo in adults with CF [3] . This suggests a genetic predisposition or an environmental factor present in early childhood as the cause. The well recognized phenotypic variability in CF is influenced by the CFTR mutation class, modifier genes, and environment factors in ways that are only partially understood.
The CF transmembrane regulator protein is expressed in the cholangiocytes of the bile duct epithelium. CFTR is not expressed in hepatocytes. Altered chloride channel transport leads to sluggish bile flow with the retention of toxic bile acids [1 ]. This in turn leads to inflammation following the induction of hepatic stellate cells, and peribiliary fibrosis. The characteristic feature of CFLD is focal biliary fibrosis which in a small proportion of children progresses to multilobular biliary cirrhosis with the development of portal hypertension [3] .
It is thought that single copy gene mutations commonly regarded as recessive may act as dominants when found in conjunction with the CF genotype. The variability in disease severity in CFLD may be determined by the presence of modifier genes [14, 15] . CFLD is associated with the Z allele of Serpina1 gene, (formerly alpha-1antitrypsin) and it is thought that in CF individuals with the Z allele of Serpina1 are at increased risk of developing CFLD [14] . The Serpina1 polymorphism is relatively uncommon in CF, approximately 2.2% of CF patients are carriers, but the odds ratio (OR) for association with CFLD is relatively high for the contribution of a genetic modifier to a Mendelian disorder at 5.04 [95% confidence
Key points
Cystic fibrosis liver disease (CFLD) represents a worse phenotype in CF and may be a risk factor for mortality in CF. Liver transplantation is becoming an acceptable treatment option for patients with liver disease in CF, but should be considered while lung function is reasonably well preserved. Newer animal models in CF offer exciting opportunities to understand the pathobiology of CFLD.
interval (CI) 2.8-8.8, P < 0.001] [14, 15] . Serpina1 is not a modifier of lung disease in CF [16] .
Serpina1 protein is mainly expressed in hepatocytes and is a serine protease inhibitor. The protein encoded by the Z allele is mis-folded and accumulates in the endoplasmic reticulum of the hepatocyte, resulting in cell death, hepatic inflammation and fibrosis. In less than 10% of Z allele homozgotes, mis-folding and accumulation of the mutant Serpina1 protein in hepatocytes causes neonatal hepatitis which eventually progresses to advanced fibrosis in 2-3% of children [15] .
The mechanism by which Serpina1 modifies liver disease in CF is likely a dual effect of Serpina1 protein accumulation in hepatocytes and peribiliary inflammation secondary to the accumulation of abnormal bile salts in the periportal areas leading to biliary cirrhosis. The identification of modifier genes in CFLD offers the exciting potential of predicting those at risk of CFLD at the time of diagnosis of CF. Currently, further genome-wide scans are underway to evaluate the possibility of other modifier genes in CFLD.
The outcome of cystic fibrosis liver disease
The diagnosis of clinically significant CFLD, as has been stated, is not straight forward [2, 3] , and this has led to a degree of uncertainty regarding the outcome for CFLD. Some studies suggest that patients with CFLD has a shorter life expectancy [17] , whereas other studies suggest that CFLD does not affect mortality or morbidity [18] . These differences may be explained in part by the use of less stringent criteria including abnormal liver function tests to define liver disease in CF in a number of studies compared to studies which have only included participants with clinical evidence of portal hypertension.
Rowland et al. [19 ] have recently shown, in what is the first study to compare the outcome of clinically significant CFLD with a well matched control group of patients with CF but no evidence of CFLD, that even in the short to medium term, a diagnosis of liver disease in CF poses a substantial threat to the well being of children with CFLD. In addition to having a reduced life expectancy, approximately 10% will either die from liver complications or need liver transplant and 30% will develop varices. They are also more likely to have a 'severe' disease phenotype with poorer disease activity scores (Shwachman score) altered body composition with reduced fat mass and higher risk of developing cystic fibrosis related diabetes.
In a recent study from the UK Cystic Fibrosis Registry, Chamnan et al. [20 ] have shown that in addition to diabetes, sex and pulmonary function, CFLD was associated with increased risk of mortality in CF (Cox hazard ratio 1.3, 95% CI 1.0-1.7). In this study the criterion for the diagnosis of liver disease included abnormal liver function test, taking ursodeoxycholic acid (URSO), or cirrhosis with portal hypertension.
A surprising finding of the study by Rowland et al. [19 ] was that whereas over 75% of children with CFLD had poorer outcome, there was a lack of evidence of progressive liver disease in a further 22% of patients at follow-up. The most distinguishing feature of this group of children over the 7 years of follow-up compared with the group whose liver disease progressed is that their spleen size remained static or decreased over time, whereas the group of participants with progressive liver disease had definite evidence of increasing spleen size after a diagnosis of CFLD was first considered. Unfortunately, none of this group had a liver biopsy, or hepatic venous gradients measured, but it is interesting to note that in a study by Lewindon et al. [9 ] , two patients developed portal hypertension in the absence of fibrosis, supporting the contention by Witters et al.
[21 ] that in CFLD portal hypertension can be out of proportion with the degree of liver fibrosis, suggesting a noncirrhotic presinusoidal vascular component to portal hypertension in CFLD [22 ] . Regardless of the reasons, it is clear that a number of children with good evidence of clinically significant liver disease in childhood will not show progression of liver disease over time [19 ] , adding further to the enigma that is CF liver disease [22 ] . At present there are no markers to indicate who will develop progressive liver disease, or which children might benefit from therapeutic or nutritional interventions. Careful histological evaluation may be able to identify portal venopathy with or without fibrosis on liver biopsy [22 ] .
Nutrition in cystic fibrosis liver disease
Outcome in CF is inextricably linked to good nutrition, and improved outcome is achievable with targeted nutritional interventions. There is a clinical and statistically significant difference in body composition between participants with CFLD and controls both in the baseline study of CFLD [6] and at 7 years follow-up [19 ] . In particular, 56% of participants with CFLD had an upper arm fat mass less than the 10th centile compared to 16% of controls after 7 years of follow-up [19 ] . Analysis of previous data collected on a subset of this group of patients suggests that children who develop CFLD have dropped off their centile track in the years prior to diagnosis of CFLD (unpublished data). A role for poor nutrition in the pathogenesis of CFLD has not been established. An important question to be addressed is whether poor nutrition leads to CFLD or whether the 
Animal models of cystic fibrosis liver disease
For years progress in understanding the mechanism of disease in CF has been hindered by the lack of a suitable animal model for this multiorgan disease. ]. The ferret model has a number of advantages in that its lung anatomy and lung cell biology are similar to humans and it reproduces rapidly, and reaches maturity in 4-6 months. Whereas the ferret had elevated plasma alanine amino-transferase (ALT) and bilirubin, with reduced cholesterol levels, which responded to treatment with Urso, the newborn ferret had no histopathological evidence of liver disease [25 ] . In contrast, the pig model, which has overall more severe gastrointestinal disease, displayed a micro-gallbladder, with evidence of abnormal bile production and early histological evidence of focal biliary cirrhosis [26 ] . It will be interesting to see if either the ferret or the pig model develops the characteristic changes of CFLD on liver biopsy when they are allowed to grow to maturity.
An interesting study by Rogan et al.
[27 ] examined insulin-like growth factor 1 (IGF1) at birth in pigs. The pig model, which like humans has a reduced birth weight, also has reduced IGF1 at birth, likely due to reduced IGF1 activity in utero. This suggests that reduced IGF1 is not only due to pulmonary inflammation or malnutrition, but that CFTR may have a more direct effect on growth hormone regulation through the pituitary which expresses CFTR, and explains the reduced birth weight in CF.
Management of cystic fibrosis liver disease
The insidious nature of CFLD hinders the potential to develop effective preventive strategies. Once estab-lished there is no treatment for CFLD. With successful banding of oesophageal varices, few patients with CFLD die from variceal haemorrhage. Liver transplantation is becoming more common in patients with end stage liver disease.
Ursodeoxycholic acid
There is no evidence that URSO is effective in the management of CFLD [3, 28] . Whereas it has been shown to reverse biochemical abnormalities in a number of cholestatic liver diseases including CFLD [3] , studies to date on the use of URSO for the management of CFLD have not been of sufficient quality to determine whether URSO is effective in CFLD. Long-term parallel randomized controlled trials with careful classification of patients with liver disease are required to demonstrate if URSO has any therapeutic benefit in CFLD. Suggestions that URSO may prevent CFLD in children with meconium ileus are unlikely to show longterm benefit [29 ] . Contrary to earlier evidence it has been shown in a number of studies that children with meconium ileus are not at increased risk of CFLD [6, 13 ] .
Liver transplantation in cystic fibrosis liver disease
An important question in the transplant era is whether patients with CFLD should be considered for transplant. It is now accepted that the presence of gastrooesophageal varices should not preclude assessment for lung transplant, and there is some consensus that isolated liver transplantation should be considered before there is significant evidence of liver decompensation. Reviews of liver transplantation for CFLD in the past year suggest that it is successful with both 1 and 5-year survival post transplant in excess of 75% [5 ,30 -32 ] . However, there are no guidelines for the optimal timing for liver transplant in patients with CFLD, though liver transplant recipients with a forced expiratory volume in 1 second (FEV1) of less than 50% have a worse outcome [32 ] . A review of the UNOS database suggests that there is little difference in the outcome for combined liver and lung transplant compared to isolated liver transplant but the numbers with combined liver and lung transplant to date are small [5 ] . Nash et al. [32 ] suggest that there is no difference in outcome for lung transplant recipients between those with and without liver disease. However, it is difficult from the data presented to determine the severity of the portal hypertension pretransplant in those with liver disease [32 ] . Of the six only one had a variceal haemorrhage and data on the elective management of varices are not presented [32 ] . The improvement in nutrition and lung function following liver transplant support the consideration of liver transplant as an option prior to onset of liver failure in CF.
Conclusion
Recent research suggests that children and adults with CFLD may have a more severe phenotype, but longer follow-up is required to determine if liver disease is an independent risk factor for mortality in CF. The development of new animal models of CFLD including the pig and the ferret offer the exciting potential to disentangle the cause and effect relationship between poor nutrition and the development of liver disease in CF. This study examines IGF1 in newborn pigs and suggests deficiency of IGF1 may be due to factors other than pulmonary inflammation or malnutrition as previously reported, and may explain differences in birth weight between CF pigs and their non-CF littermates. This study confirms that liver disease is not a contraindication to lung transplant in CF. However, it is unclear as to the severity of the liver disease in the group of six transplanted patients as only one had a history of varices, and preoperative albumin, bilirubin or platelet data are not presented.
